Binimetinib: Phase III data

Pierre Fabre has exclusive, worldwide rights, excluding the U.S., Canada, Japan, Korea and Israel, to develop and commercialize binimetinib and encorafenib from Array (see BioCentury, Nov. 23, 2015). ...